Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 2, 2012, Pages 155-160

  Tasian, Gregory E ^a   Cooperberg, Matthew R ^a,b   Cowan, Janet E ^a   Keyashian, Kian ^a,c   Greene, Kirsten L ^a   Daniels, Nicholas A ^d   Carroll, Peter R ^a,b   Chan, June M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer screening; Physician decision; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SCREENING; DEMOGRAPHY; DIGITAL RECTAL EXAMINATION; FEMALE; GENERAL PRACTITIONER; HEALTH CARE UTILIZATION; HUMAN; HUMAN EXPERIMENT; MALE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PROPENSITY SCORE; PROSTATE CANCER; QUESTIONNAIRE; SCORING SYSTEM;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; PROGNOSIS; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK FACTORS;

EID: 84857640743     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.12.019     Document Type: Article

References (21)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341:1781-1788.
3. Potosky A.L., Feuer E.J., Levin D.L. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 2001, 23:181-186.
4. Albertsen P.C., Fryback D.G., Storer B.E., et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995, 274:626-631.
5. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006, 24:46-50.
6. Smith R.A., Cokkinides V., Brawley O.W. Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009, 59:27-41.
7. Scardino P. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2005, 3(Suppl 1):S29-S33.
8. Lin K., Lipsitz R., Miller T., et al. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008, 149:192-199.
9. Ferrini R., Woolf S.H. American College of Preventive Medicine practice policy. Screening for prostate cancer in American men. Am J Prev Med 1998, 15:81-84.
10. Kim H.L., Benson D.A., Stern S.D., et al. Practice trends in the management of prostate disease by family practice physicians and general internists: an internet-based survey. Urology 2002, 59:266-271.
11. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med 2004, 350:2239-2246.
12. Hoffman R.M., Couper M.P., Zikmund-Fisher B.J., et al. Prostate cancer screening decisions: Results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med 2009, 169:1611-1618.
13. Hoffman R.M., Papenfuss M.R., Buller D.B., et al. Attitudes and practices of primary care physicians for prostate cancer screening. Am J Prev Med 1996, 12:277-281.
14. Edlefsen K.L., Mandelson M.T., McIntosh M.W., et al. Prostate-specific antigen for prostate cancer screening. Do physician characteristics affect its use?. Am J Prev Med 1999, 17:87-90.
15. Moran W.P., Cohen S.J., Preisser J.S., et al. Factors influencing use of the prostate-specific antigen screening test in primary care. Am J Manag Care 2000, 6:315-324.
16. Stroud L., Ross L.E., Rose S.W. Formative evaluation of the prostate cancer screening practices of African-American physicians. J Natl Med Assoc 2006, 98:1637-1643.
17. Purvis-Cooper C., Merritt T.L., Ross L.E., et al. To screen or not to screen, when clinical guidelines disagree: Primary care physicians' use of the PSA test. Prev Med 2004, 38:182-191.
18. Austin O.J., Valente S., Hasse L.A., et al. Determinants of prostate-specific antigen test use in prostate cancer screening by primary care physicians. Arch Fam Med 1997, 6:453-458.
19. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149:185-191. U.S. Preventive Services Task Force.
20. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
21. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.